ArticleGynecologic oncology reports2025
Risk factors and clinical outcomes of radiation-induced fistula after chemoradiation and image-guided brachytherapy for locally advanced cervical cancer.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rectovaginal fistulas after radiation therapy: treatment options and outcomes - a narrative review.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose/Objectives: The standard treatment for locally advanced cervical cancer (LACC) is concurrent chemoradiation and brachytherapy (CRT-B). Fistula formation is a serious complication of pelvic radiation; however, risk factors and outcomes are not well described. We sought to identify the incidence, risk factors and prognosis of radiation-induced fistula in women who underwent CRT-B for LACC. Materials/Methods: Patients with FIGO IB2-IV cervical cancer treated with CRT-B at a single institution from 2013 to 2022 were reviewed. Patient and treatment characteristics were analyzed. The primary endpoint was fistula incidence. Logistic regression model was performed to assess factors associated with fistula. Fistula-free survival and overall survival were estimated using the Kaplan-Meier method. Results: Thirteen (9 %) of 150 reviewed patients developed fistula with median follow up of 20 months (CI: 22.8-35.4). Fistula symptoms resolved in 8/13 patients (62 %). Two-year overall survival and fistula-free survival was 72.0 % (CI: 62.6-79.5) and 91.6 % (CI: 84.9-95.4), respectively. On univariate analysis, higher BMI was associated with decreased fistula risk (OR 0.90, CI: 0.82-1.00; p = 0.048). Current smoking (OR 8.37, CI: 2.58-27.22; p < 0.001), lack of MRI guidance (OR 4.77, CI: 1.42-15.97; p = 0.011) and disease extension into bladder (OR 3.99, CI: 1.27-12.53; p = 0.018), were associated with increased fistula risk. On multivariable analysis, only current smoking (OR 5.14, CI: 1.43-18.48; p = 0.012) was associated with increased fistula risk. Conclusions: Patients treated with CRT-B for LACC have a 9% risk of fistula formation. MRI guidance may be useful in brachytherapy planning to reduce the risk of toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.